Facial palsy in individuals with thalidomide embryopathy: frequency and characteristics by Sjögreen, L. & Kiliaridis, S.
Facial palsy in individuals with thalidomide
embryopathy: frequency and characteristics
L SJÖGREEN1, S KILIARIDIS2
1Mun-H-Center Orofacial Resource Centre for Rare Diseases and Department of Speech Pathology, Institute of
Neuroscience and Physiology, Sahlgrenska Academy at Gothenburg University, Sweden, and 2Department of
Orthodontics, Dental School, University of Geneva, Switzerland
Abstract
Background: Earlier studies have shown that individuals with thalidomide embryopathy can have skeletal
deformities, ear and eye aberrations, and facial palsy. This study aimed to survey the frequency and
characteristics of facial palsy in this group of individuals.
Participants: Thirty-one individuals with thalidomide embryopathy (age range, 45–47 years) and 25 healthy
adults (age range, 41–56 years; mean age± standard deviation, 49± 4.2 years).
Main outcome measures: Voluntary facial movements, lip force and three-dimensional lip motion analysis.
Results and conclusion: Four of the thalidomide embryopathy individuals (13 per cent) had congenital facial
palsy. All four had eye aberrations, three had ear anomalies and one had a limb anomaly. Individuals with
thalidomide embryopathy without a clinical diagnosis of facial impairment had significantly weaker lips and
more restricted lip mobility than healthy controls. This study contributes to the overall knowledge of
thalidomide embryopathy by adding a description of how facial expression can be affected in this condition.
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Introduction
In 1961, it was discovered that women who had taken
the drug thalidomide in early pregnancy gave birth to
children with multiple anomalies.1
Strömland and Miller’s 1993 study of 86 Swedish
individuals with thalidomide embryopathy found that
the drug caused not only skeletal deformities but also
eye aberrations (in 54 per cent) and facial palsy (in
17 per cent).2 The authors noted that facial palsy,
ocular motility defects and abnormal lacrimation
occurred in individuals who had been exposed to thali-
domide early in their gestation period, but not in those
who had isolated anomalies occurring as a result of
later exposure. Strömland and Miller confirmed that
thalidomide exerts its effects on the development of
the cranial nerves early in the teratogenic period, prob-
ably mainly during the fourth week of development.
The present study of the occurrence of facial palsy in
individuals with thalidomide embryopathy was part of
a multidisciplinary follow-up investigation of a subset
of Swedish thalidomide embryopathy individuals, per-
formed approximately 50 years after thalidomide was
introduced to the market.3,4 Facial palsy has previously
been recognised as an effect of thalidomide embryopa-
thy but has not been described in any detail.
Therefore, the present study aimed to survey the fre-
quency and characteristics of facial palsy in this group
of individuals.
Materials and methods
Individuals with thalidomide embryopathy were
invited to participate in a multidisciplinary study via
a letter distributed by The Swedish Association of
Thalidomide Embryopathy. At that time, there were
108 members, of which 84 were on the mailing list.
Fifty individuals replied to the invitation, and 31 (18
men and 13 women) took part in the study. All were
aged between 45 and 47 years. Congenital anomalies
were common and affected the upper limb (27 individ-
uals), lower limb (7), ears (9) and eyes (12).
The results from the examinations of individuals
without facial impairment were compared to those
from 25 healthy adults (seven men and 18 women;
age range, 41–56 years; mean age± standard devi-
ation, 49± 4.2 years).
The examinations were conducted at Mun-H-Center,
a national orofacial resource centre for rare diseases.
Informed consent was obtained from each partici-
pant, and the study was approved by the ethics
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committee of the Medical Faculty at the University of
Gothenburg.
Voluntary facial movements
Video recordings of voluntary facial movements and
facial muscles at rest were independently evaluated
by two speech-language pathologists according to the
definitions described in the Sunnybrook Facial
Grading System.5,6 In cases of disagreement on any
variable, the two examiners watched the video record-
ing together and made a consensus decision. Both
examiners knew beforehand whether the individual
had thalidomide embryopathy or not.
The facial expressions studied were gentle eye
closure, open mouthed smile, snarl and lip pucker.
The participants repeated the facial expressions twice
with a short break in between. The degree of muscle
excursion during voluntary movements was evaluated
on a five-point scale with the following definitions:
1= unable to initiate movement; 2= initiates slight
movement; 3= initiates movement with mid-excur-
sion; 4=movement almost complete; and 5=move-
ment complete. Any synkinetic movements
accompanying the voluntary movements were also
recorded if present. Resting symmetry was noted
while the patient looked at a picture for 30 seconds,
and was described as normal or affected. Recordings
were made with two calibrated digital video cameras
(Sony XC-HR50; Sony, Tokyo, Japan). The two
cameras were positioned approximately 80 cm in
front of the participant and 25 cm apart.
Lip mobility
The three-dimensional position of the oral commis-
sures was measured from the video recordings using
SmartEye Pro 3.7 Mimic Muscle Evaluation software
(SmartEye, Gothenburg, Sweden).7,8 This information
was used to calculate mouth width (i.e. the distance
between the oral commissures), mouth width change
during different facial expressions compared to the
rest position, and mouth width asymmetry. The
method we used for computerised evaluation of lip
mobility has been previously described in detail by
Sjögreen et al.8
Lip force
Lip force was measured using an LF100 instrument
(Detektor, Göteborg, Sweden) connected to an
oral screen (Ulmer model; Dentarum, Pforzheim,
Germany).8,9 Patients were seated in a stable position
and instructed to keep the oral screen inside their lips
while the examiner pulled the handle. The LF100 instru-
ment recorded the maximum value measured during 10
seconds. The best of three measurements was saved.
The LF100 instrument was not included in the study
from outset, and therefore lip force was only measured
in 29 patients. All lip force measurements were made
by the same speech-language pathologist (LS).
Statistical analysis
The Statistical Package for the Social Sciences for
Windows (version 15.0) software program was used to
calculate descriptive statistics and to analyse groupdiffer-
ences (using theMann–Whitney U test) and correlations
between groups (using Pearson’s correlation coefficient).
Results and analysis
Voluntary facial movements
Six of the 31 individuals with thalidomide embryopa-
thy (19 per cent) had a Sunnybrook Facial Grading
System score of less than 4 on any side, or both
sides, for one or more of the facial expressions
studied (Table I). Five had a known diagnosis of
facial palsy and one had Parkinson’s disease.
Case seven had an acquired, unilateral facial palsy
due to a stroke. The only remaining symptom was
delayed muscle contraction on the right side during
open-mouthed smiling. Voluntary lip movements
were complete and the face was symmetrical at rest.
Case 11 had a bilateral facial palsy, congenital on the
left side and acquired on the right due to ear surgery.
All facial muscles were severely affected.
Case 16 had a congenital, unilateral facial palsy
severely affecting the muscles elevating the left
corner of the mouth. Lip pucker was performed with
complete movements on both sides but the mouth
deviated to the healthy side.
Case 24 had a congenital facial palsy affecting only
the muscle depressor labii inferioris on the right side.
TABLE I
DATA FOR TE CASES WITH DIAGNOSED FACIAL EXPRESSION IMPAIRMENT∗
Case no Sex Diagnosis Asym at rest? SFGS score (left/right)
Eye closure OM smile Snarl Pucker
7 M Unilateral facial palsy No 5/5 5/5 5/5 5/5
11 M Bilateral facial palsy Yes 4/4 2/1 1/1 1/1
16 F Unilateral facial palsy Yes 5/3 5/1 5/3 5/5
19 F Parkinson’s disease No 5/3 3/3 3/3 5/5
24 M Unilateral facial palsy No 5/5 4/5 3/5 5/5
25 F Bilateral facial palsy Yes 5/4 4/3 5/3 5/5
∗Sunnybrook Facial Grading System (SFGS) score of less than 4 for at least one facial expression; see text for explanation of scores.
TE= thalidomide embryopathy; no= number; Asym= asymmetrical; OM= open mouthed; M=male; F= female
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Case 25 had an asymmetrical, bilateral facial palsy,
congenital on the right side and acquired on the left.
The congenital facial palsy was more severe than the
acquired, and the face was asymmetrical at rest.
Case 19 had hypokinetic facial movements because
of Parkinson’s disease. None of the participants
showed synkinetic movements.
All four individuals with congenital facial palsy had
ocular motility defects (Duane syndrome) and anoma-
lous tearing,4 three had ear anomalies, one had an
upper limb anomaly, and none had lower limb
anomalies. Two with bilateral facial palsy had mild
dysarthria (cases 11 and 25). Upper face involvement
(cases 11, 16 and 25) or impairment of a single
branch of the facial nerve (case 24) indicated that the
facial palsy was peripheral in these cases.
Lip mobility
Table II gives individual measures of lip mobility, in
terms of mouth width, mouth width change and
mouth width asymmetry, for the six participants with
thalidomide embryopathy and facial impairment.
Table III presents results for the same parameters for
those participants with thalidomide embryopathy who
did not have a diagnosed facial impairment, and also
for healthy adult controls. The healthy adults had a
broader smile and a larger mouth width change in an
open mouthed smile than the thalidomide embryopathy
individuals without facial impairment (p = 0.002,
z=− 3.134); however, there was no difference
between these groups concerning mouth width in lip
pucker (p= 0.171, z=− 1.368) or at rest (p= 0.915,
z=− 0.107). Three individuals with facial impairment
had a mouth width change in an open mouthed smile
and in a lip pucker that wasmore than two standard devi-
ations lower than the mean of the healthy group. In the
group of individuals with thalidomide embryopathy and
no recognised facial impairment (n= 25), seven indi-
viduals had values lower than two standard deviations
from the mean of the healthy adults in an open
mouthed smile, and one in a lip pucker (borderline).
Lip force
The individuals with thalidomide embryopathy and no
recognised facial impairment had weaker lips than the
healthy adults (p= 0.004, z=− 2.481) (Figure 1).
There was a weak but significant correlation between
lip force and mouth width change in an open
mouthed smile (p = 0.006, r = 371) but not in a
lip pucker (p= 0.259, r=− 0.156). However, the
only individual with impaired lip pucker according to
their Sunnybrook Facial Grading System score had
very weak lips (case 11).
Discussion
Congenital facial nerve palsy is one of the anomalies
that can be associated with thalidomide embryopathy,
and it is often combined with ocular motility defects
caused by abducens nerve palsy.2,10 This combination
of symptoms is also known as Möbius sequence and
is recognised as a possible sign of an early embryonic
insult.11 The facial palsy seen in Möbius sequence is
often bilateral; in contrast, the congenital palsy seen
in the present study was unilateral.12 Congenital
facial palsy is also a frequent finding in other con-
ditions involving malformations caused by early preg-
nancy incidents, such as Goldenhar syndrome and
‘CHARGE’ syndrome (the latter comprising colo-
boma, heart abnormalities, retardation of growth and/
or development, and genital and ear anomalies).13–17
Five individuals (16 per cent) in the present study
had a previous diagnosis of facial palsy, and one had
bilaterally incomplete facial movements because of
Parkinson’s disease. Three individuals (10 per cent)
had an acquired facial palsy, of whom two already
had congenital nerve palsy on the opposite side. This
is more than can be expected by chance, and may indi-
cate that the facial nerve is more vulnerable in this
population.18 There was no characteristic feature of
impaired facial expression in the group. Sometimes,
only one single branch of the facial nerve seemed to
be affected. The facial palsy interfered with facial
expression and facial appearance, but speech was
affected (i.e. dysarthria was present) only when there
was bilateral impairment.
Lip force and the mean value for mouth width
change in an open mouthed smile were reduced for
TABLE II
LIP MOBILITY RESULTS∗: TE CASES WITH DIAGNOSED
FACIAL PALSY†
Case no SFGS score
(L/R)
MW
(mm)
MWC
(mm)
MWA
(%)
Mouth at rest
7 47.9 – 4.3
11 53.0 – 5.8
16 49.9 – 20.4‡
19 44.4 – 19.5‡
24 53.9∗∗ – 4.1
25 43.7∗∗ – 2.9
Open mouthed
smile
7 5/5 62.0 14.1 1.2
11 2/1 49.3‡ −3.6‡ 6.7∗∗
16 5/1 58.7∗∗ 8.8‡ 6.4∗∗
19 3/3 53.0∗∗ 8.6‡ 14.5‡
24 4/5 70.9 17.0 0.7
25 4/3 57.8∗∗ 14.2 4.3
Lip pucker
7 5/5 27.3 −20.6 4.6
11 1/1 47.9‡ −5.1‡ 9.2
16 5/5 28.5 −21.4 42.1‡
19 5/5 28.9 −15.4∗∗ 24.5∗∗
24 5/5 30.5 −23.3 15.5
25 5/5 26.5 −17.2 27.5
∗Mouth width (MW), mouth width change from rest to maximal
expression (MWC) and relative mouth width asymmetry (MWA),
from three-dimensional motion analysis of lip mobility.
†Sunnybrook Facial Grading System (SFGS) score of less than
4 for at least one facial expression. ‡Value is >2 standard devi-
ations (SDs) lower than mean for healthy controls; ∗∗value is
>1 SD lower than mean for healthy controls. TE= thalidomide
embryopathy; no= number; L= left; R= right
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thalidomide embryopathy individuals without facial
impairment, compared with healthy individuals. This
could imply that some individuals with thalidomide
embryopathy had a mild facial weakness that had not
been clinically identified.
Following subjective evaluation of the facial
muscles, assessment was completed by taking objec-
tive measurements of lip mobility and lip force, via
computerised video analysis and a lip force measuring
device. Results from the measuring devices confirmed
most of the subjective evaluations; however, there was
a risk that all results may have been affected by the fact
that the examiners were not blinded to the participants’
thalidomide diagnosis. In two cases, there was a discre-
pancy between the results of objective and subjective
evaluation of facial asymmetry at rest. This discrepancy
could be due to the fact that subjective evaluation
involved the whole face, whereas objective measure-
ments were calculated only from the three-dimensional
position of the oral commissures.
In their 2010 methodological study, Sjögreen et al.
explored the same quantitative methods for evaluation
of lip mobility and lip force which were used in the
present study.8 This study suggested threshold values
for lip force (12 Newton) and mouth width change in
open mouthed smile (9 mm) and in a lip pucker
(11 mm) which could identify adults with impaired
lip function. The suggested thresholds for lip force
and for mouth width change in a lip pucker were
observed to be adequate for predictive purposes in
the present study. However, the suggested threshold
for mouth width change in an open mouthed
smile seemed to be less able to predict impaired lip
function.
• Thalidomide embryopathy can cause skeletal,
ear and eye abnormalities and facial palsy
• This study assessed facial expression in
thalidomide embryopathy patients
• There was no typical pattern of facial palsy
severity or distribution
• All patients with facial palsy also had
impaired eye motility
• Patients without substantial facial
impairment had poorer lip force and mobility
The present study contributes to the overall picture of
thalidomide embryopathy by adding a description of
how facial expression can be affected in this condition.
There seems to be no typical expression of facial palsy
in thalidomide embryopathy, regarding severity and
distribution.
Conclusion
Individuals with thalidomide embryopathy can have
skeletal deformities, ear and eye aberrations, and
facial palsy. This study gives a more detailed descrip-
tion of how individuals’ facial expression can be
affected by this condition.
We found that there was no typical expression of
facial palsy in thalidomide embryopathy, regarding
severity and distribution. All individuals with thalido-
mide embryopathy and facial palsy also had impaired
eye motility. Individuals with thalidomide embryopa-
thy who did not have clinically diagnosed facial
impairment were observed to have significantly
weaker lips and more restricted lip mobility, compared
with healthy controls.
TABLE III
LIP MOBILITY RESULTS∗: TE CASES WITH NO KNOWN FACIAL PALSY AND CONTROLS
Facial expression TE† Controls†
MW (mm) MWC (mm) MWA (%) MW (mm) MWC (mm) MWA (%)
Mouth at rest 49.6± 3.9 – 4.5± 5.2 49.2± 4.5 – 5.0± 3.1
Open mouthed smile 61.4± 4.4 11.8± 3.7 3.8± 4.7 65.8± 4.3 16.6± 3.1 3.4± 2.2
Lip pucker 30.8± 4.0 −18.8± 5.2 9.4± 7.9 29.0± 4.8 −20.2± 4.9 10.5± 8.9
Data represent means± standard deviations. ∗Mouth width (MW), mouth width change from rest to maximal expression (MWC) and relative
mouth width asymmetry (MWA), from three-dimensional motion analysis of lip mobility. †N= 25. TE= thalidomide embryopathy cases
with no known facial palsy
FIG. 1
Maximal lip force measured in 29 thalidomide embryopathy indi-
viduals and 25 healthy controls, using the LF100 instrument.
THALIDOMIDE EMBRYOPATHY AND FACIAL PALSY 905
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0022215112001429
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 14:29:55, subject to the Cambridge Core terms of use, available at
Acknowledgements
We thank dental nurse Linda Tjärnström Gustafsson for
invaluable assistance with practical procedures, and
speech-language pathologist Åsa Mogren for help with the
assessments. Special thanks also go to Professor Anette
Lohmander and Professor Kerstin Strömland for contributing
their knowledge and expertise. We are also grateful to the
other members of the multidisciplinary team involved in
the project for their fruitful cooperation, and to all the indi-
viduals who participated in the study.
References
1 Lenz W. A short history of thalidomide embryopathy.
Teratology 1988;38:203–15
2 Strömland K, Miller MT. Thalidomide embryopathy: revisited
27 years later. Acta Ophthalmol (Copenh) 1993;71:238–45
3 Ekfeldt A, Carlsson GE. Dental status and oral function in an
adult group of subjects with thalidomide embryopathy – a clini-
cal and questionnaire study. Acta Odontol Scand 2008;66:
300–6
4 Miller MT, Strömland K, Ventura L. Congenital aberrant
tearing: a re-look. Trans Am Ophthalmol Soc 2008;106:100–16
5 Ross BG, Fradet G, Nedzelski JM. Development of a sensitive
clinical facial grading system. Otolaryngol Head Neck Surg
1996;114:380–6
6 Neely JG, Cherian NG, Dickerson CB, Nedzelski JM.
Sunnybrook facial grading system: reliability and criteria for
grading. Laryngoscope 2010;120:1038–45
7 Schimmel M, Christou P, Houstis O, Herrmann FR, Kiliaridis S,
Muller F. Distances between facial landmarks can be measured
accurately with a new digital 3-dimensional video system. Am J
Orthod Dentofacial Orthop 2010;137:580.e1–10
8 Sjögreen L, Lohmander A, Kiliaridis S. Exploring quantitative
methods for evaluation of lip function. J Oral Rehabil 2011;
38:410–22
9 Hägg M, Olgarsson M, Anniko M. Reliable lip force measure-
ment in healthy controls and in patients with stroke: a methodo-
logic study. Dysphagia 2008;23:291–6
10 Miller MT, Strömland K. Ocular motility in thalidomide
embryopathy. J Pediatr Ophthalmol Strabismus 1991;28:47–54
11 Marques-Dias MJ, Gonzalez CH, Rosemberg S. Möbius
sequence in children exposed in utero to misoprostol: neuro-
pathological study of three cases. Birth Defects Res A Clin
Mol Teratol 2003;67:1002–7
12 Sjögreen L, Andersson-Norinder J, Jacobsson C. Development
of speech, feeding, eating, and facial expression in Möbius
sequence. Int J Pediatr Otorhinolaryngol 2001;60:197–204
13 Strömland K, Miller M, Sjögreen L, JohanssonM, Joelsson BM,
Billstedt E et al. Oculo-auriculo-vertebral spectrum: associated
anomalies, functional deficits and possible developmental risk
factors. Am J Med Genet A 2007;143A:1317–25
14 Touliatou V, Fryssira H, Mavrou A, Kanavakis E, Kitsiou-Tzeli
S. Clinical manifestations in 17 Greek patients with Goldenhar
syndrome. Genet Couns 2006;17:359–70
15 Carvalho GJ, Song CS, Vargervik K, Lalwani AK. Auditory and
facial nerve dysfunction in patients with hemifacial microsomia.
Arch Otolaryngol Head Neck Surg 1999;125:209–12
16 Blake KD, Hartshorne TS, Lawand C, Dailor AN, Thelin JW.
Cranial nerve manifestations in CHARGE syndrome. Am J
Med Genet A 2008;146A:585–92
17 Strömland K, Sjögreen L, Johansson M, Ekman Joelsson B-M,
Miller M, Danielsson S et al. CHARGE association in Sweden:
malformations and functional deficits. Am J Med Genet A 2005;
133A:331–9
18 Katusic SK, Beard CM,Wiederholt WC, Bergstralh EJ, Kurland
LT. Incidence, clinical features, and prognosis in Bell’s palsy,
Rochester, Minnesota, 1968–1982. Ann Neurol 1986;20:622–7
Address for correspondence:
Dr Lotta Sjögreen,
Mun-H-Center, Odontologen,
Medicinaregatan 12 A,
SE-413 90 Göteborg, Sweden
Fax: + 46 31 750 92 01
E-mail: lotta.sjogreen@vgregion.se
Dr L Sjögreen takes responsibility for the integrity of the
content of the paper
Competing interests: None declared
L SJÖGREEN, S KILIARIDIS906
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0022215112001429
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 14:29:55, subject to the Cambridge Core terms of use, available at
